Using a Fan With Aromatherapy in Breathlessness Patients in Terminal Illness

Terminal Illness Clinical Trial

Official title:

The Effect of Using a Fan With Aromatherapy in Breathlessness Patient in Terminally Illness: a Randomized Control Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05625854
• Other study ID #: fan for dyspnea
• Status: Enrolling by invitation
• Phase: N/A
• Start date: November 25, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2022
• Source: Taipei Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Difficulty breathing is a very devastating symptom, often seen in terminal patients. Accompanied by physical, psychological, emotional, and social limitations, Not to mention the ambiguity in the occurrence of dyspnea symptoms and the difficulty in obtaining satisfactory quality of symptom care. The purpose of this study is to confirm the use of non-drug interventions in clinical situations, such as fans and aromatherapy to alleviate the complications of end-stage patients. The effectiveness of the symptoms of dyspnea.

Description:

Difficulty breathing is a very devastating symptom, often seen in terminal patients. Accompanied by physical, psychological, emotional, and social limitations, Not to mention the ambiguity in the occurrence of dyspnea symptoms and the difficulty in obtaining satisfactory quality of symptom care. The purpose of this study is to confirm the use of non-drug interventions in clinical situations, such as fans and aromatherapy to alleviate the complications of end-stage patients. The effectiveness of the symptoms of dyspnea.

Inclusion criteria

1. Over 20 years old.

2. It is determined by the physician to meet the final diagnosis conditions.

3. Symptoms of dyspnea.

4. The daily physical status of patients is assessed using the East Coast Cancer Clinical Research Cooperative Organization Assessment Scale (Eastern Cooperative Oncology Group, ECOG) ≧ 2 points.

5. Able to communicate in Mandarin or Taiwanese or written conversation.

6. Unconscious disorder.

7. After explaining and explaining, agree to participate in this research and sign the consent form.

Exclusion criteria

1. Receive treatment for facial trigeminal nerve damage.

2. Abnormal sense of smell.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 99
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Over 20 years old.

2. It is determined by the physician to meet the final diagnosis conditions.

3. Symptoms of dyspnea.

4. The status of patients is assessed using the East Coast Cancer Clinical Research Cooperative Organization Assessment Scale (ECOG) ? 2 points.

5. Able to communicate in Mandarin or Taiwanese or written conversation.

6. Conscience clear.

7. After explaining and explaining, agree to participate in this research and sign the consent form.

Exclusion Criteria:

1. Receive treatment for facial trigeminal nerve damage.

2. Abnormal sense of smell.

Related Conditions & MeSH terms

• Aromatherapy
• Breathlessness
• Dyspnea
• Terminal Illness

Intervention

Behavioral:
• Blow a fan to the face combine aromatherapy
Blow a fan with aromatherapy to the face
• Blow a fan to the face
Blow a fan to the face
• Blow a fan to the feet
Blow a fan to the feet

Locations

Country	Name	City	State
Taiwan	Taipei Medical University	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Tsai-Wei Huang

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chinese version of the Respiratory Distress Observation Scale,C-RDOS	RDOS is an eight-item ordinal scale designed to measure the presence and intensity of respiratory distress in adults. High score means high respiratory distress.	The score change up to three days.
Secondary	Patient Health Questionnaire (PHQ-9)	The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day). It has been validated for use in primary care.[2]; It is not a screening tool for depression but it is used to monitor the severity of depression and response to treatment. high score mean higher emotion distress.	The score change up to three days.
Secondary	Chinese version of the Edmonton Symptom Assessment System,C-ESAS	The ESAS includes 11 symptoms: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, sleep, well-being, shortness of breath, and other. It uses a 0-10 numerical scale: 0 shows the absence of a symptom, and 10 shows the worst experience of the symptom.	The score change up to three days.
Secondary	Smart bracelet_Heart rate variability (HRV)	HRV is the physiological phenomenon of the variation in the time interval between consecutive heartbeats in milliseconds. A normal, healthy heart does not tick evenly like a metronome, but instead, when looking at the milliseconds between heartbeats, there is constant variation.	Continue wear bracelet five days to record HRV data.